Dyadic International (DYAI)

$DYAI Here is the link PR to the presentation https://seekingalpha.com/pr/20436701-life-sciences-virtual-investor-forum-presentations-now-available-for-online-viewing

$DYAI https://seekingalpha.com/pr/20438093-dyadic-applied-biosolutions-announces-commercial-distribution-partnership-with-ibt

$DYAI 07:22 on Mar. 16 2026 Dyadic Applied BioSolutions Enters Into Original Equipment Manufacturer Distribution Agreement With Integrated Biotherapeutics To Expand Protein Product Reach #tradeideas

$DYAI Listen to the presentation, they have a lot of products hitting the market, and more to come in 2027, 2028. Revenue coming. Market under-estimating now.

The B2i Digital team is pleased to announce that Dyadic Applied BioSolutions (Nasdaq: $DYAI) is participating in the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, on Thursday, March 12, 2026, at 1:30 PM EDT. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/otc-life-sciences-virtual-investor-forum Virtual Investor Conferences brings together public companies and a global audience of retail and institutional investors for live executive presentations, Q&A sessions, and on-demand replays. The platform is open to public companies listed on NYSE, Nasdaq, TSX, CSE, ASX, and the OTC Markets. Dyadic is a global biotechnology company focused on the scalable production of high-value, precision-engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications. Presenting on behalf of Dyadic will be Joe Hazelton, President and Chief Operating Officer. Mr. Hazelton joined Dyadic in 2021 as Chief Business Officer and was promoted to his current role in 2024, bringing more than two decades of leadership in biotech commercialization with experience at both Dyadic and Novartis. To register for this presentation, visit: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5262339/dyadic-international-nasdaq-dyai?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC For more information about Dyadic International, visit: https://dyadic.com/investors/overview/ Content about any specific company was provided and approved by that company or is available in the public domain. B2i Digital, Inc. has not independently verified the accuracy of the information contained herein. The content contained herein is informational only, and no content contained herein shall be considered an offer to solicit the sale of any security or make a recommendation to purchase a security. B2i Digital is not a broker-dealer or investment adviser.

$DYAI ALERT – FIRST COMMERCIAL - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6819130

MOMO'S BREAKOUT BOARD : 🚨 $DYAI ALERT – FIRST COMMERCIAL... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177375682 via @Investors_Hub

🚨 $DYAI ALERT – FIRST COMMERCIAL PRODUCT LAUNCHED ! 🔥🧬💥 🔹Dyadic + Fermbox Bio just dropped animal-origin-free Recombinant DNase I (RNase-Free) – FIRST product under expanded collab! Animal-free biotech beast transitioning HARD to sales + recurring rev in life sciences! 🔹Fresh off Inzymes dairy enzyme milestone ($200K cash + royalties in $1.5–$2B market) – 2026 commercialization ramp loading. Sustainable proteins play exploding! 🔹Nasdaq micro-cap with catalyst volume spikes – traders: pops incoming. Investors: diamond hands on green biotech revolution. 🔹Don't fade this undervalued runner! 📈🌱 https://youtube.com/shorts/VvNJ34sZpQE?feature=share #TheBullRunShow #DYAI #Biotech #AnimalFree #PrecisionFermentation #PennyStocks #HighAlert @Dyadic_Inc @TheBullRunShow @DAVANZO

$DYAI entered an at-the-market sales agreement with Craig-Hallum

$DYAI where is my post regarding SEC filings and ATM buffered?